GAK
ENSG00000178950
Target class
Kinase
Chromosome
4
- Chemical probe available
- Yes
- Other names
- DNAJC26
- Target name
- GAK
- Gene name
- Cyclin G associated kinase
- Gene symbol
- GAK
- Protein name
- Cyclin-G-associated kinase (EC 2.7.11.1) (DnaJ homolog subfamily C member 26)
- Gene biotype
- Protein coding
- Gene family
- DNAJ (HSP40) heat shock proteins|C2 tensin-type domain containing
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 89.33
- Tissue specificity (Gini)
- 0.244
- Tissue specificity (tau)
- 0.499
- KEGG gene identifiers
- hsa:2580
- Protein interaction confidence
- 0.832233
- Protein interaction partners
- 30
- R-HSA-432722
- R-HSA-8856828
- End position
- 932411
- Start position
- 849275
- Chromosome
- 4
- Strand
- Reverse
- Cytoplasm, perinuclear region . Golgi apparatus, trans-Golgi network . Cell junction, focal adhesion . Cytoplasmic vesicle, clathrin-coated vesicle . Note=Localizes to the perinuclear area and to the trans-Golgi network. Also seen on the plasma membrane, probably at focal adhesions. Recruitment to clathrin-coated vesicles depends on temporal variations in phosphoinositide composition of clathrin-coated vesicles (PubMed:31962345). .
- Golgi apparatus
- Vesicles
- PubMed 10625686
- PubMed 31962345
- Tissue specificity (tau)
- 0.498715
- Expression inequality (Gini)
- 0.243896
Expression in transcripts per million
- Testis
- 89.33
- Spleen
- 78.8
- Uterus
- 76.23
- Brain - Cerebellum
- 75.83
- Cervix - Endocervix
- 71.96
Expression in transcripts per million
- Testis89.33
- Spleen78.8
- Uterus76.23
- Brain - Cerebellum75.83
- Cervix - Endocervix71.96
- Brain - Cerebellar Hemisphere71.67
- Fallopian Tube71.48
- Lung70.25
- Minor Salivary Gland69.4
- Small Intestine - Terminal Ileum68.32
- Thyroid64.06
- Ovary62.44
- Cervix - Ectocervix60.18
- Prostate60.07
- Nerve - Tibial58.6
- Vagina57.4
- Colon - Transverse56.45
- Pituitary55.22
- Bladder54.76
- Skin - Sun Exposed (Lower leg)49.91
- Esophagus - Mucosa49.8
- Cells - EBV-transformed lymphocytes49.47
- Artery - Aorta49.38
- Skin - Not Sun Exposed (Suprapubic)48.51
- Stomach47.92
And 29 more, listed on the interactive page.
- GO:0006457
- GO:0006898
- GO:0007030
- GO:0010977
- GO:0034067
- GO:0048268
- GO:0072318
- GO:0072583
- GO:0072659
- GO:0090160
- GO:1905443
- GO:0005794
- GO:0005829
- GO:0016020
- GO:0030136
- GO:0031982
- GO:0004674
- GO:0005515
- GO:0044183
Related records
Trials (170)
- "Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.
- A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants
- A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable
- A Moderate to Severe Rheumatoid Arthritis Study
- A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease
- A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas
- A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
- A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients
- A Relative Bioavailability and Food Effect Study of New Formulations
- A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis
- A Study in Moderate to Severe Rheumatoid Arthritis
- A Study in Moderate to Severe Rheumatoid Arthritis Participants
- A Study in Participants With Moderate to Severe Rheumatoid Arthritis
- A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy
- A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
- A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS
- A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis
- A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
- A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
- A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata